Adefovir dipivoxil
- Generic Name
- Adefovir dipivoxil
- Brand Names
- Hepsera
- Drug Type
- Small Molecule
- Chemical Formula
- C20H32N5O8P
- CAS Number
- 142340-99-6
- Unique Ingredient Identifier
- U6Q8Z01514
- Background
Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon and Hepsera, is an orally-administered acyclic nucleotide analog reverse transcriptase inhibitor (ntRTI) used for treatment of hepatitis B. It is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.
- Indication
Indicated for the treatment of chronic hepatitis B in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease; this is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and in adult patients with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function.
- Associated Conditions
- Chronic Hepatitis B Infection
A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
- Conditions
- HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2012-04-25
- Lead Sponsor
- Bukwang Pharmaceutical
- Target Recruit Count
- 43
- Registration Number
- NCT00641082
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Bundang, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Novartis
- Registration Number
- NCT00606099
- Locations
- 🇺🇸
Novartis, Sterling, Virginia, United States
A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy
- Conditions
- Hepatitis B
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2010-07-07
- Lead Sponsor
- Hospital Authority, Hong Kong
- Target Recruit Count
- 70
- Registration Number
- NCT00489151
- Locations
- 🇨🇳
Queen Mary Hospital, Hong Kong, China
Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2009-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1470
- Registration Number
- NCT00441974
- Locations
- 🇨🇳
GSK Investigational Site, Tianjin, China
Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2011-06-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 43
- Registration Number
- NCT00376259
- Locations
- 🇺🇸
Novartis, San Diego, California, United States
🇨🇳Novarits, Kaohsuing, Taiwan
Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis
- Conditions
- Hepatitis B, ChronicCirrhosisFibrosisChronic Hepatitis B
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 155
- Registration Number
- NCT00347009
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh City, Vietnam
Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 40
- Registration Number
- NCT00307242
Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2007-11-15
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 19
- Registration Number
- NCT00230477
- Locations
- 🇺🇸
Harborview Medical Center, Seattle, Washington, United States
Effect of Age on the Renal Clearance of Adefovir
- Conditions
- Other Conditions That May Be A Focus of Clinical Attention
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-11-21
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT00187746
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV.
- Conditions
- Hepatitis B
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 107
- Registration Number
- NCT00158717
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.